comprehensive
Previous article:
FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article: CommonSpirit Health keeps growing, even as it loses money
Next article: CommonSpirit Health keeps growing, even as it loses money
hotspot
leisure time
-
Intarcia’s device
2025-10-02 20:00 -
Acelyrin, a rare IPO success, stumbles in its first big test
2025-10-02 19:20 -
What to make of Biden’s latest efforts on cancer research
2025-10-02 18:45 -
Telehealth for opioid use disorder is lifesaving
2025-10-02 17:47 -
Long Covid needs a new name — and a new frame
2025-10-02 17:40 -
Intarcia’s device
2025-10-02 17:24